Miramar Capital LLC increases its equity holdings in Johnson & Johnson (NYSE:JNJ)


Miramar Capital LLC increased its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.9% during the first quarter, HoldingsChannel reports. The company held 51,340 shares of the company after acquiring an additional 956 shares during the period. Johnson & Johnson accounts for about 2.5% of Miramar Capital LLC’s investment portfolio, making the stock its 18th largest holding. Miramar Capital LLC’s holdings in Johnson & Johnson were worth $9,099,000 when it last filed with the Securities and Exchange Commission (SEC).

A number of other institutional investors also bought and sold shares of JNJ. Family CFO Inc bought a new stake in Johnson & Johnson stock during the 4th quarter valued at around $26,000. RE Dickinson Investment Advisors LLC raised its position in Johnson & Johnson shares by 163.3% in the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company valued at $28,000 after purchasing an additional 98 shares during the period. Advanced Research Investment Solutions LLC increased its position in Johnson & Johnson shares by 200.0% during the 1st quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company valued at $32,000 after purchasing an additional 120 shares during the period. Professional Financial Advisors LLC increased its position in Johnson & Johnson shares by 47.9% during the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company valued at $37,000 after purchasing an additional 68 shares during the period. Finally, Joseph P. Lucia & Associates LLC purchased a new equity stake in Johnson & Johnson during Q1 valued at approximately $38,000. 68.78% of the shares are held by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

NYSE: JNJ opened Wednesday at $166.13. The company has a fifty-day simple moving average of $173.32 and a two-hundred-day simple moving average of $174.48. The company has a market capitalization of $436.79 billion, a price-to-earnings ratio of 24.18, a growth price-to-earnings ratio of 3.22 and a beta of 0.59. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt ratio of 0.37. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.

Johnson & Johnson Inc (NYSE:JNJ – Get Rating) last released its quarterly results on Tuesday, July 19. The company reported EPS of $2.59 for the quarter, beating the consensus estimate of $2.57 by $0.02. The company posted revenue of $24.02 billion in the quarter, versus a consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The company’s quarterly revenue increased 3.0% compared to the same quarter last year. In the same quarter a year earlier, the company posted earnings per share of $2.48. As a group, stock analysts expect Johnson & Johnson to post earnings per share of 10.05 for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6. Investors of record on Tuesday, August 23 will receive a dividend of $1.13 per share. The ex-dividend date is Monday, August 22. This represents a dividend of $4.52 on an annualized basis and a dividend yield of 2.72%. Johnson & Johnson’s payout ratio is currently 65.79%.

Insider buying and selling

Separately, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a trade on Friday, June 10. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company, valued at $12,336,803. The sale was disclosed in a legal filing with the SEC, accessible via the SEC’s website. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the company in a trade Thursday, May 26. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following completion of the transaction, the chief accounting officer now owns 15,473 shares of the company, valued at $2,785,140. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, accessible via this hyperlink. Additionally, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a trade on Friday, June 10. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company, valued at approximately $12,336,803. The disclosure of this sale can be found here. Insiders own 0.35% of the shares of the company.

Changes to analyst ratings

JNJ has been the subject of several analyst reports. UBS Group cut its price target on Johnson & Johnson shares from $185.00 to $180.00 in a Thursday, July 21 research report. SVB Leerink reduced its target price on Johnson & Johnson from $200.00 to $194.00 in a Wednesday July 20 research report. Daiwa Capital Markets began covering Johnson & Johnson in a research report on Wednesday June 22. They issued an “outperformance” rating on the stock. Wells Fargo & Company raised its price target on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a Wednesday, July 13 research report. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong buy” rating in a Tuesday, May 17 research report. Four investment analysts gave the stock a hold rating, five issued a buy rating and one gave the company’s stock a strong buy rating. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Company Profile

(Get an assessment)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

Read more

Want to see what other hedge funds own JNJ? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Get Rating).

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.

Comments are closed.